Genetics of stroke: a review of recent advances

References

• Dominiczak AF, McBride MW. Genetics of common polygenic stroke. Nat. Genet.35(2), 116–117 (2003).
   PubMed Web of Science ®Google Scholar
• Gretarsdottir S, Thorleifsson G, Reynisdottir ST et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet.35(2), 131–138 (2003).
   PubMed Web of Science ®Google Scholar
• International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature449(7164), 851–861 (2007).
   PubMed Web of Science ®Google Scholar
• Clayton TA, Lindon JC, Cloarec O et al. Pharmaco–metabonomic phenotyping and personalized drug treatment. Nature440(7087), 1073–1077 (2006).
   PubMed Web of Science ®Google Scholar
• Gabriel RA, Yang GY. Gene therapy in cerebrovascular diseases. Curr. Gene Ther.7(6), 421–433 (2007).
   PubMedGoogle Scholar
• Vila N. A genetic approach to ischemic stroke therapy. Cerebrovasc. Dis.17(Suppl. 1), 63–69 (2004).
   PubMedGoogle Scholar
• Günel M, Lifton RP. Counting strokes. Nat. Genet.13(4), 384–385 (1996).
   PubMedGoogle Scholar
• Kiyohara Y, Kubo M, Kato I et al. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. Stroke34(10), 2343–2347 (2003).
   PubMedGoogle Scholar
• Otero Palleiro MM, Barbagelata López C. Etiologic subtypes of ischemic stroke in young adults aged 18 to 45 years: a study of a series of 93 patients. Rev. Clin. Esp.207(4), 158–165 (2007).
   PubMedGoogle Scholar
• Lee M, Huang WY, Weng HH, Lee JD, Lee TH. First-ever ischemic stroke in very old Asians: clinical features, stroke subtypes, risk factors and outcome. Eur. Neurol.58(1), 44–48 (2007).
   PubMedGoogle Scholar
• Adams HP Jr, Woolson RF, Clarke WR et al. Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Control. Clin. Trials18(4), 358–377 (1997).
   PubMedGoogle Scholar
• Towfighi A, Greenberg SM, Rosand J. Treatment and prevention of primary intracerebral hemorrhage. Semin. Neurol.25(4), 445–452 (2005).
   PubMedGoogle Scholar
• No authors listed. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke20(10), 1407–1431 (1989).
   PubMed Web of Science ®Google Scholar
• Feigin VL. Stroke epidemiology in the developing world. Lancet365(9478), 2160–2161 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson DW, Furlan AJ. Clinical epidemiology of stroke. Neurosurg. Clin. N. Am.8(2), 265–269 (1997).
   PubMedGoogle Scholar
• Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation113(24), E873–E9230 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke37(6), 1583–1633 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Hankey GJ. Advances in primary stroke prevention. Stroke37(2), 317–319 (2006).
   PubMedGoogle Scholar
• Hart CL, Hole DJ, Smith GD. Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland. Stroke30(10), 1999–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Marmot MG, Poulter NR. Primary prevention of stroke. Lancet339(8789), 344–347 (1992).
   PubMed Web of Science ®Google Scholar
• Sacco RL. Newer risk factors for stroke. Neurology57(5 Suppl. 2), S31–S34 (2001).
   PubMed Web of Science ®Google Scholar
• Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke23(2), 221–223 (1992).
   PubMed Web of Science ®Google Scholar
• Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke33(3), 769–774 (2002).
   PubMed Web of Science ®Google Scholar
• Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham Study. Stroke24(9), 1366–1371 (1993).
   PubMed Web of Science ®Google Scholar
• Liao D, Myers R, Hunt S et al. Familial history of stroke and stroke risk. The Family Heart Study. Stroke28(10), 1908–1912 (1997).
   PubMed Web of Science ®Google Scholar
• Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke35(4), 819–824 (2004).
   PubMed Web of Science ®Google Scholar
• Tournier-Lasserve E. New players in the genetics of stroke. N. Engl. J. Med.347(21), 1711–1712 (2002).
   PubMed Web of Science ®Google Scholar
• Joutel A, Corpechot C, Ducros A et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature383(6602), 707–710 (1996).
   PubMed Web of Science ®Google Scholar
• Tournier-Lasserve E, Joutel A, Melki J et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat. Genet.3(3), 256–259 (1993).
   PubMed Web of Science ®Google Scholar
• Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke24(1), 122–125 (1993).
   PubMed Web of Science ®Google Scholar
• Ruchoux MM, Guerouaou D, Vandenhaute B, Pruvo JP, Vermersch P, Leys D. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol.89(6), 500–512 (1995).
   PubMed Web of Science ®Google Scholar
• Chabriat H, Tournier-Lasserve E, Vahedi K et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology45(6), 1086–1091 (1995).
   PubMed Web of Science ®Google Scholar
• Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling pathway. Am. J. Hum. Genet.74(2), 338–347 (2004).
   PubMedGoogle Scholar
• Dichgans M, Ludwig H, Müller-Höcker J, Messerschmidt A, Gasser T. Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur. J. Hum. Genet.8(4), 280–285 (2000).
   PubMedGoogle Scholar
• Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the a-galactosidase A gene that cause Fabry disease. Am. J. Hum. Genet.53(6), 1186–1197 (1993).
   PubMedGoogle Scholar
• Nance CS, Klein CJ, Banikazemi M et al. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch. Neurol.63(3), 453–457 (2006).
   PubMedGoogle Scholar
• Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med.9(1), 34–45 (2007).
   PubMed Web of Science ®Google Scholar
• Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JM. Recombinant enzyme therapy for Fabry disease: absence of editing of human a-galactosidase A mRNA. Am. J. Hum. Genet.72(1), 23–31 (2003).
   PubMedGoogle Scholar
• Clarke JT. Narrative review: Fabry disease. Ann. Intern. Med.146(6), 425–433 (2007).
   PubMed Web of Science ®Google Scholar
• Hendricks HT, Franke CL, Theunissen PH. Cerebral amyloid angiopathy: diagnosis by MRI and brain biopsy. Neurology40(8), 1308–1310 (1990).
   PubMed Web of Science ®Google Scholar
• Greenberg SM. Genetics of primary intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis.11(5), 265–271 (2002).
   PubMedGoogle Scholar
• Tonk M, Haan J. A review of genetic causes of ischemic and hemorrhagic stroke. J. Neurol. Sci.257(1–2), 273–279 (2007).
   PubMed Web of Science ®Google Scholar
• Haan J, Kluft C, Leebeek FW, de Bart AC, Buruma OJ, Roos RA. Hereditary cerebral hemorrhage with amyloidosis-Dutch type: a study of fibrinolysis. Thromb. Haemost.67(1), 16–18 (1992).
   PubMedGoogle Scholar
• Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol.49(6), 697–705 (2001).
   PubMed Web of Science ®Google Scholar
• Jensson O, Gudmundsson G, Arnason A et al. Hereditary cystatin C (γ-trace) amyloid angiopathy of the CNS causing cerebral hemorrhage. Acta Neurol. Scand.76(2), 102–114 (1987).
   PubMed Web of Science ®Google Scholar
• Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K. Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat. Genet.13(4), 429–434 (1996).
   PubMed Web of Science ®Google Scholar
• Jeffs B, Clark JS, Anderson NH et al. Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat. Genet.16(4), 364–367 (1997).
   PubMed Web of Science ®Google Scholar
• Gretarsdottir S, Sveinbjörnsdottir S, Jonsson HH et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am. J. Hum. Genet.70(3), 593–603 (2002).
   PubMed Web of Science ®Google Scholar
• Dichgans M. Genetics of ischaemic stroke. Lancet Neurol.6(2), 149–161 (2007).
   PubMed Web of Science ®Google Scholar
• Rosand J, Bayley N, Rost N, de Bakker PI. Many hypotheses but no replication for the association between PDE4D and stroke. Nat. Genet.38(10), 1091–1092 (2006).
   PubMed Web of Science ®Google Scholar
• Woo D, Kaushal R, Kissela B et al. Association of phosphodiesterase 4D with ischemic stroke: a population-based case–control study. Stroke37(2), 371–376 (2006).
   PubMed Web of Science ®Google Scholar
• Nakayama T, Asai S, Sato N, Soma M. Genotype and haplotype association study of the STRK1 region on 5q12 among Japanese: a case–control study. Stroke37(1), 69–76 (2006).
   PubMedGoogle Scholar
• Saleheen D, Bukhari S, Haider SR et al. Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population. Stroke36(10), 2275–2277 (2005).
   PubMedGoogle Scholar
• Van Rijn MJ, Slooter AJ, Schut AF et al. Familial aggregation, the PDE4D gene, and ischemic stroke in a genetically isolated population. Neurology65(8), 1203–1209 (2005).
   PubMedGoogle Scholar
• Meschia JF, Brott TG, Brown RD Jr et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann. Neurol.58(3), 351–361 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhlenbäumer G, Berger K, Huge A et al. Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort. J. Neurol. Neurosurg. Psychiatry77(4), 521–524 (2006).
   PubMedGoogle Scholar
• Nilsson-Ardnor S, Wiklund PG, Lindgren P et al. Linkage of ischemic stroke to the PDE4D region on 5q in a Swedish population. Stroke36(8), 1666–1671 (2005).
   PubMedGoogle Scholar
• Bevan S, Porteous L, Sitzer M, Markus HS. Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis. Stroke36(5), 949–953 (2005).
   PubMed Web of Science ®Google Scholar
• Lõhmussaar E, Gschwendtner A, Mueller JC et al.ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke36(4), 731–736 (2005).
   PubMed Web of Science ®Google Scholar
• Kostulas K, Gretarsdottir S, Kostulas V et al. PDE4D and ALOX5AP genetic variants and risk for ischemic cerebrovascular disease in Sweden. J. Neurol. Sci.263(1–2), 113–117 (2007).
   PubMed Web of Science ®Google Scholar
• Fidani L, Clarimon J, Goulas A et al. Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population. Eur. J. Neurol.14(7), 745–749 (2007).
   PubMedGoogle Scholar
• Staton JM, Sayer MS, Hankey GJ et al. Association between phosphodiesterase 4D gene and ischaemic stroke. J. Neurol. Neurosurg. Psychiatry77(9), 1067–1069 (2006).
   PubMed Web of Science ®Google Scholar
• Song Q, Cole JW, O’Connell JR et al. Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study. Hum. Mol. Genet.15(16), 2468–2478 (2006).
   PubMed Web of Science ®Google Scholar
• Zee RY, Brophy VH, Cheng S, Hegener HH, Erlich HA, Ridker PM. Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case–control evaluation. Stroke37(8), 2012–2017 (2006).
   PubMed Web of Science ®Google Scholar
• Brophy VH, Ro SK, Rhees BK et al. Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status. Stroke37(6), 1385–1390 (2006).
   PubMedGoogle Scholar
• Helgadottir A, Manolescu A, Thorleifsson G et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet.36(3), 233–239 (2004).
   PubMed Web of Science ®Google Scholar
• Dixon RA, Diehl RE, Opas E et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature343(6255), 282–284 (1990).
   PubMed Web of Science ®Google Scholar
• Shen CD, Zhang WL, Sun K, Wang YB, Zhen YS, Hui RT. Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter case-control study. Ann. Hum. Genet.71(Pt 5), 620–629 (2007).
   PubMedGoogle Scholar
• Kaushal R, Pal P, Alwell K et al. Association of ALOX5AP with ischemic stroke: a population-based case–control study. Hum. Genet.121(5), 601–607 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang WL, Yang XM, Shi J, Sun K, Hui RT. Polymorphism of SG13S114T/A in the ALOX5AP gene and the risk for stroke in a large Chinese cohort. Yi Chuan Xue Bao33(8), 678–684 (2006).
   PubMedGoogle Scholar
• Kajimoto K, Shioji K, Ishida C et al. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ. J.69(9), 1029–1034 (2005).
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Gretarsdottir S, St Clair D et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet.76(3), 505–509 (2005).
   PubMed Web of Science ®Google Scholar
• Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case–control approach. Stroke37(8), 2007–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Nilsson-Ardnor S, Janunger T, Wiklund PG et al. Genome-wide linkage scan of common stroke in families from northern Sweden. Stroke38(1), 34–40 (2007).
   PubMedGoogle Scholar
• Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet.6(2), 95–108 (2005).
   PubMed Web of Science ®Google Scholar
• Funalot B, Varenne O, Mas JL. A call for accurate phenotype definition in the study of complex disorders. Nat. Genet.36(1), 3 (2004).
   PubMedGoogle Scholar
• Woo D, Sekar P, Chakraborty R et al. Genetic epidemiology of intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis.14(6), 239–243 (2005).
   PubMedGoogle Scholar
• Greenberg SM, Vonsattel JP, Segal AZ et al. Association of apolipoprotein E ε2 and vasculopathy in cerebral amyloid angiopathy. Neurology50(4), 961–965 (1998).
   PubMed Web of Science ®Google Scholar
• Kaushal R, Woo D, Pal P, Haverbusch M et al. Subarachnoid hemorrhage: tests of association with apolipoprotein E and elastin genes. BMC Med. Genet.8, 49 (2007).
   PubMed Web of Science ®Google Scholar
• Woo D, Kaushal R, Chakraborty R et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke36(9), 1874–1879 (2005).
   PubMedGoogle Scholar
• Woo D, Sauerbeck LR, Kissela BM et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke33(5), 1190–1195 (2002).
   PubMed Web of Science ®Google Scholar
• Gould DB, Phalan FC, van Mil SE et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N. Engl. J. Med.354(14), 1489–1496 (2006).
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Davis JP, Graffagnino C et al. Endoglin gene polymorphism as a risk factor for sporadic intracerebral hemorrhage. Ann. Neurol.41(5), 683–686 (1997).
   PubMedGoogle Scholar
• Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. Stroke29(4), 813–816 (1998).
   PubMed Web of Science ®Google Scholar
• Gemmati D, Serino ML, Ongaro A et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am. J. Hematol.67(3), 183–188 (2001).
   PubMed Web of Science ®Google Scholar
• Nadel JA. Genetics reveals importance of platelet activating factor in asthma and possibly other inflammatory states. J. Clin. Invest.97(12), 2689–2690 (1996).
   PubMedGoogle Scholar
• Slowik A, Turaj W, Dziedzic T et al. DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. Neurology63(2), 359–361 (2004).
   PubMed Web of Science ®Google Scholar
• Navarro-Núñez L, Lozano ML, Rivera J et al. The association of the β1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica92(4), 513–518 (2007).
   PubMed Web of Science ®Google Scholar
• McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology53(6), 1308–1311 (1999).
   PubMed Web of Science ®Google Scholar
• Banerjee I, Gupta V, Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. J. Hum. Genet.52(3), 205–219 (2007).
   PubMed Web of Science ®Google Scholar
• Sudlow C, Martínez González NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke37(2), 364–370 (2006).
   PubMed Web of Science ®Google Scholar
• Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch. Neurol.61(11), 1652–1661 (2004).
   PubMed Web of Science ®Google Scholar
• Ariyaratnam R, Casas JP, Whittaker J, Smeeth L, Hingorani AD, Sharma P. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med.4(4), E131 (2007).
   PubMed Web of Science ®Google Scholar
• Zee RY, Cook NR, Cheng S et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum. Mol. Genet.13(4), 389–396 (2004).
   PubMedGoogle Scholar
• Berger K, Stögbauer F, Stoll M et al. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case–control studies. Hum. Genet.121(2), 169–178 (2007).
   PubMedGoogle Scholar
• Keijzer MB, den Heijer M, Blom HJ et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb. Haemost.88(5), 723–728 (2002).
   PubMed Web of Science ®Google Scholar
• Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA288(16), 2023–2031 (2002).
   PubMed Web of Science ®Google Scholar
• Baum L, Wong KS, Ng HK et al. Methylenetetrahydrofolate reductase gene A222V polymorphism and risk of ischemic stroke. Clin. Chem. Lab. Med.42(12), 1370–1376 (2004).
   PubMed Web of Science ®Google Scholar
• Choi BO, Kim NK, Kim SH et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Thromb. Res.111(1–2), 39–44 (2003).
   PubMed Web of Science ®Google Scholar
• Kohara K, Fujisawa M, Ando F et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: the NILS-LSA Study. Stroke34(5), 1130–1135 (2003).
   PubMed Web of Science ®Google Scholar
• Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J. Med. Sci.47(6), 255–262 (2001).
   PubMedGoogle Scholar
• Morita H, Kurihara H, Tsubaki S et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler. Thromb. Vasc. Biol.18(9), 1465–1469 (1998).
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Rosand J, Kistler JP et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology59(4), 529–536 (2002).
   PubMed Web of Science ®Google Scholar
• Gu CC, Chang YP, Hunt SC et al. Haplotype association analysis of AGT variants with hypertension-related traits: the HyperGEN study. Hum. Hered.60(3), 164–176 (2005).
   PubMed Web of Science ®Google Scholar
• Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet.51(1), 197–205 (1992).
   PubMed Web of Science ®Google Scholar
• Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest.86(4), 1343–1346 (1990).
   PubMed Web of Science ®Google Scholar
• Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum. Genet.115(2), 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature359(6396), 641–644 (1992).
   PubMed Web of Science ®Google Scholar
• Sirgo G, Pérez-Vela JL, Morales P et al. Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery. Intensive Care Med.32(5), 668–675 (2006).
   PubMedGoogle Scholar
• Wiklund PG, Nilsson L, Ardnor SN et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case–control studies based on independent cohorts. Stroke36(8), 1661–1665 (2005).
   PubMed Web of Science ®Google Scholar
• Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin. Med. J. (Engl.)116(11), 1707–1710 (2003).
   PubMedGoogle Scholar
• Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke34(12), 2822–2828 (2003).
   PubMedGoogle Scholar
• Zhang C, Li J, Li L, Luo B. The study of PAI-1 promotor region gene polymorphism in cerebrovascular disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi18(5), 383–387 (2001).
   PubMedGoogle Scholar
• Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc. Dis.11(4), 294–299 (2001).
   PubMed Web of Science ®Google Scholar
• Elbaz A, Cambien F, Amarenco P. Plasminogen activator inhibitor genotype and brain infarction. Circulation103(2), E13–E14 (2001).
   Google Scholar
• Endler G, Lalouschek W, Exner M, Mitterbauer G, Häring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br. J. Haematol.110(2), 469–471 (2000).
   PubMed Web of Science ®Google Scholar
• Roest M, van der Schouw YT, Banga JD et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation101(1), 67–70 (2000).
   PubMed Web of Science ®Google Scholar
• Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb. Haemost.77(4), 730–734 (1997).
   PubMed Web of Science ®Google Scholar
• Ding J, Nicklas BJ, Fallin MD et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am. Heart J.152(6), 1109–1115 (2006).
   PubMed Web of Science ®Google Scholar
• Jood K, Ladenvall P, Tjärnlund-Wolf A et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke36(10), 2077–2081 (2005).
   PubMedGoogle Scholar
• van Goor ML, García EG, Leebeek F, Brouwers GJ, Koudstaal P, Dippel D. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case–control study. Thromb. Haemost.93(1), 92–96 (2005).
   PubMedGoogle Scholar
• Chen CH, Eng HL, Chang CJ et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J. Lab. Clin. Med.142(2), 100–105 (2003).
   PubMed Web of Science ®Google Scholar
• Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J. Cardiovasc. Risk9(2), 131–137 (2002).
   PubMedGoogle Scholar
• Reiner AP, Schwartz SM, Frank MB et al. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke32(11), 2580–2586 (2001).
   PubMed Web of Science ®Google Scholar
• Akar N, Akar E, Yilmaz E, Deda G. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. J. Child Neurol.16(4), 294–295 (2001).
   PubMedGoogle Scholar
• Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann. Intern. Med.140(5), 330–337 (2004).
   PubMed Web of Science ®Google Scholar
• Steen M, Norstrøm EA, Tholander AL et al. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood103(9), 3381–3387 (2004).
   PubMed Web of Science ®Google Scholar
• Matarín M, Brown WM, Scholz S et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol.6(5), 414–420 (2007).
   PubMed Web of Science ®Google Scholar
• Kubo M, Hata J, Ninomiya T et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat. Genet.39(2), 212–217 (2007).
   PubMed Web of Science ®Google Scholar
• Cupples LA, Arruda HT, Benjamin EJ et al. The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med. Genet.8(Suppl. 1), S1 (2007).
   PubMedGoogle Scholar
• Larson MG, Atwood LD, Benjamin EJ et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med. Genet.8(Suppl. 1), S5 (2007).
   Google Scholar
• McPherson R, Pertsemlidis A, Kavaslar N et al. A common allele on chromosome 9 associated with coronary heart disease. Science316(5830), 1488–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Bergthorsson JT, Agnarsson BA, Gudbjartsson T et al. A genome-wide study of allelic imbalance in human testicular germ cell tumors using microsatellite markers. Cancer Genet. Cytogenet.164(1), 1–9 (2006).
   PubMedGoogle Scholar
• Abbott A. With your genes? Take one of these, three times a day. Nature425(6960), 760–762 (2003).
   PubMedGoogle Scholar
• Evans WE, McLeod HL. Pharmacogenetics – drug disposition, drug targets, and side effects. N. Engl. J. Med.348(6), 538–549 (2003).
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA279(15), 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenetics in reducing adverse drug reactions: a systematic review. JAMA286(18), 2270–2279 (2001).
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N. Engl. J. Med.348(6), 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• No authors listed. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med.333(24), 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Alvarez-Sabín J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke35(2), 486–490 (2004).
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet350(9078), 607–614 (1997).
   PubMed Web of Science ®Google Scholar
• Dubinsky R, Lai SM. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample. Neurology66(11), 1742–1744 (2006).
   PubMedGoogle Scholar
• Sheehan JJ, Tsirka SE. Fibrin-modifying serine proteases thrombin, rt-PA, and plasmin in ischemic stroke: a review. Glia50(4), 340–350 (2005).
   PubMed Web of Science ®Google Scholar
• Broderick J, Lu M, Jackson C et al. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann. Neurol.49(6), 736–744 (2001).
   PubMedGoogle Scholar
• Ladenvall P, Nilsson S, Jood K, Rosengren A, Blomstrand C, Jern C. Genetic variation at the human tissue-type plasminogen activator (rt-PA) locus: haplotypes and analysis of association to plasma levels of rt-PA. Eur. J. Hum. Genet.11(8), 603–610 (2003).
   PubMed Web of Science ®Google Scholar
• Montaner J, Fernández-Cadenas I, Molina CA et al. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke34(12), 2851–2855 (2003).
   PubMed Web of Science ®Google Scholar
• Fernández-Cadenas I, Alvarez Sabín J, Molina CA et al. ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke. Neurologia21(4), 176–180 (2006).
   PubMedGoogle Scholar
• Fernández-Cadenas I, Molina CA, Alvarez-Sabín J et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci. Lett.398(3), 167–171 (2006).
   PubMedGoogle Scholar
• González-Conejero R, Fernández-Cadenas I, Iniesta JA et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke37(9), 2288–2293 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J. Thromb. Haemost.5(9), 1862–1868 (2007).
   PubMedGoogle Scholar